Skip to content Skip to footer
Subscribe Now
Bavarian Nordic
NEWS

Bavarian Nordic Announces Topline P-II Trial Data of MVA-BN Mpox/Smallpox Vaccine in Younger Population

Shots:Bavarian Nordic has reported topline P-II trial results evaluating two standard doses of the MVA-BN mpox/smallpox vaccine in 460 participants, incl. children (2–11 yrs) & adults (18–50 yrs) across 2 cohorts in the DRC & UgandaIn the trial, 227 children among 451 evaluable subjects showed a non-inferior immune response to adults (n=224) 2wks.…
October 8, 2025

Read more

New Drug Designations - August 2024
INSIGHTS+

New Drug Designations – August 2024 

Shots:  PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. August month’s report includes designations allotted to 10 small molecules, 9 biologics, 7 cell & gene therapies, 1 vaccine, 2 radiopharmaceutical, 1 peptide, 1 antineoplastic and 2 devices  In August 2024, Invenra’s INV724 received the…
September 25, 2024

Read more

New Drug Designations - May 2024
INSIGHTS+

New Drug Designations – May 2024

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the FDA, NMPA and EMA. This month’s report includes designations allotted to 12 small molecules, 7 biologics, 9 cell & gene therapies, 1 vaccine, 1 peptide, 1 RNA candidate, 1 recombinant fusion protein, 1 imaging agent and 6 devices This…
June 25, 2024

Read more

thoughtspot_alyssa bladon
THOUGHTSPOT

What Are The Signs Of A Vaccine Injury?

The signs and symptoms of a potential vaccine injury can vary. They may include symptoms such as severe pain or swelling at the injection site, whole-body rashes or hives, fever, difficulty breathing or swallowing, extreme fatigue, vomiting, or swollen lymph nodes.Other adverse reactions that could be attributed to a vaccine injury include neurological disorders…
February 28, 2023

Read more

Viewpoints_Yoshio Okubo
VIEWPOINTS

Yoshio Okubo, Senior Director, Head of Pandemic Global Product Team for Takeda Shares Insights on the Approval of its Covid-19 Vaccine

Shots:Yoshio spoke about the approval of the Nuvaxovid COVID-19 Vaccine for Primary and Booster Immunization in Japan. Nuvaxovid Intramuscular Injection is the first recombinant protein-based COVID-19 vaccine approved for use in JapanYoshio also talked about Takeda’s collaboration with Novavax for the development, manufacturing, and commercialization of Nuvaxovid in JapanFurther, the interview highlighted…
October 4, 2022

Read more